the aid library

LIST OPTIONS

Filter

7055

Sort by:

Direction:

Download (540)

View PDF (1163)

Antimicrobial resistance and causes of non-prudent use of antibiotics in human medicine in the EU

European Commission (2017) C1

Antimicrobial resistance (AMR) is an increasing worldwide public health problem with important implications for the European Union (EU). When antibiotics become ineffective, bacterial infections lead to increased morbidity, use of healthcare, mortality and cost. Globally, estimates suggest that ... more

Download (79)

View PDF (395)

Global Morbidity and Mortality of Leptospirosis: A Systematic Review

Costa, F.; Hagan, J.; Calcagno, J. PLoS Neglected Tropical diseases (2015) CC

Leptospirosis, a spirochaetal zoonosis, occurs in diverse epidemiological settings and affects vulnerable populations, such as rural subsistence farmers and urban slum dwellers. Although leptospirosis is a life-threatening disease and recognized as an important cause of pulmonary haemorrhage syndrom... more

Download (95)

View PDF (405)

The Need for Full Integration of Snakebite Envenoming within a Global Strategy to Combat the Neglected Tropical Diseases: The Way Forward

Gutiérrez, J.; Warrell, D.; Williams, D. et al. PLoS Neglected Tropical diseases (2013) CC

Snakebite envenoming constitutes a serious medical condition that primarily affects residents of rural communities in Africa, Asia, Latin America, and New Guinea. It is an occupational, environmental, and domestic health hazard that exacerbates the already impoverished state of these communities. Co... more

Download (112)

View PDF (562)

National Disability Mainstreaming Strategy and Implementation Plan (NDMS&IP) 2018-2023

Department of Disability and elderly affairs Ministry of Gender, Children, Disability and Social Welfare (2019) CC

The NDMS&IP focuses on mainstreaming disability to promote equitable access to services in the six thematic areas of health, education, livelihoods, empowerment, and social inclusion and cross-cutting issues. The first part of the NDMS&IP outlines incongruences between national and sectoral policie... more

Download (91)

View PDF (343)

Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40

Global Burden of Disease Health Financing Collaborator Network Lancet (2018) C1

Background: Achieving universal health coverage (UHC) requires health financing systems that provide prepaid pooled resources for key health services without placing undue financial stress on households. Understanding current and future trajectories of health financing is vital for progress towards ... more

Download (138)

View PDF (337)

Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3

Global Burden of Disease Health Financing Collaborator Network Lancet (2020) C1

Background: Sustainable Development Goal (SDG) 3 aims to “ensure healthy lives and promote well-being for all at all ages”. While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to ... more

Download (109)

View PDF (110)

Working Paper 46 - Aid, China, and Growth: Evidence from a New Global Development Finance Dataset

Dreher, A.; A. Fuchs; B. Parks et al. AidData at William & Mary (2017) CC

This paper introduces a new dataset of official financing—including foreign aid and other forms of concessional and non-concessional state financing—from China to 138 countries between 2000 and 2014. We use these data to investigate whether and to what extent Chinese aid affects economic growth ... more

Download (70)

View PDF (308)

Countdown to 2015: assessment of official development assistance to maternal, newborn, and child health, 2003–08

Pitt, C.; G. Greco; T. Powell-Jackson et al. Lancet (2010) C1

Background: Achievement of high coverage of effective interventions and Millennium Development Goals (MDGs) 4 and 5A requires adequate financing. Many of the 68 priority countries in the Countdown to 2015 Initiative are dependent on official development assistance (ODA). We analysed aid flows for ma... more

Download (75)

View PDF (350)

Countdown to 2015: tracking donor assistance to maternal, newborn, and child health

Powell-Jackson, T.; J. Borghi; D. Mueller et al. Lancet (2006) C1

Background: Timely reliable data on aid flows to maternal, newborn, and child health are essential for assessing the adequacy of current levels of funding, and to promote accountability among donors for attainment of the Millennium Development Goals (MDGs) for child and maternal health. We provide g... more

Download (79)

View PDF (313)

Development assistance for health and the Middle East and North Africa

Zhao, Y.; A. E. Micah; S. Gloyd et al. Globalization and Health (2020) C1

Background: Donor countries in the Middle East and North Africa (MENA) including Saudi Arabia, Kuwait and United Arab Emirates (UAE) have been among the largest donors in the world. However, little is known about their contributions for health. In this study, we addressed this gap by estimating the ... more

Download (96)

View PDF (321)

Donor Financing of Global Mental Health, 1995—2015: An Assessment of Trends, Channels, and Alignment with the Disease Burden

Charlson, F.J.; J. Dieleman, L. Singh et al. PLOS One (2017) CC

Background: A recent report by the Institute for Health Metrics and Evaluation (IHME) highlights that mental health receives little attention despite being a major cause of disease burden. This paper extends previous assessments of development assistance for mental health (DAMH) in two significant w... more

Download (126)

View PDF (207)

Financing Global Health 2014: Shifts in Funding as the MDG Era Closes

Institute for Health Metrics and Evaluation (2015) CC

Financing Global Health 2014 is the sixth edition of this annually produced report on global health financing. As in previous years, this report captures trends in development assistance for health (DAH) and government health expenditure (GHE). Health financing is one of IHME’s core research areas... more

Download (108)

View PDF (114)

Tracking aid for global health goals: a systematic comparison of four approaches applied to reproductive, maternal, newborn, and child health

Pitt C.; Grollman C.; Martinez-Alvarez M. et al The Lancet (2018) CC

Four initiatives have estimated the value of aid for reproductive, maternal, newborn, and child health (RMNCH): Countdown to 2015, the Institute for Health Metrics and Evaluation (IHME), the Muskoka Initiative, and the Organisation for Economic Co-operation and Development (OECD) policy marker. We... more

Download (49)

View PDF (175)

What counts as development assistance for reproductive, maternal, newborn, and child health?

Templin T.; Bendavid E. The Lancet (2020) CC

There is no single answer to this question, and therefore no single way to do it. In The Lancet Global Health, Antonia Dingle and colleagues report the convening of a group of policy makers to discuss why we should track financing for RMNCH. The group developed a set of principles guiding what infor... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (163)

View PDF (116)

Tuberculosis action plan for the WHO Eastern Mediterranean Region 2023-2030

World Health Organization WHO (2023) C_WHO

The World Health Organization (WHO) Global Tuberculosis Report 2021 estimated that, in 2020, tuberculosis (TB) was the second most common infectious disease killer after coronavirus disease (COVID-19) and the 13th leading cause of death (1). Twenty-five per cent (25%) of the world’s population has... more

Download (116)

View PDF (101)

Tuberculosis action plan for the WHO Eastern Mediterranean Region 2023-2030

World Health Organization WHO (2023) C_WHO

Download (115)

View PDF (122)

Sudan Humanitarian Update (23 November 2023)

OCHA (2023) CC

Since fighting between the Sudanese Armed Forces (SAF) and the Rapid Support Forces (RSF) erupted in mid-April, an estimated 6.3 million people have fled their homes, taking refuge inside and outside the country, with children representing about half of the people displaced. Sudan is now the country... more

Download (124)

View PDF (256)

Community-Based Mental Health: A Training Guide for Community Providers

International Federation of Red Cross and Red Crescent Societies IFRC (2023) CC

Mental health problems are common and cause great suffering to individuals and communities around the world. They have a significant impact not only on the physical and mental health of those affected but also on their families and the communities they live in. At the same time, all communities have... more